Major pharma firms join Liverpool Uni in £14m pharmacovigilance project
The UK’s University of Liverpool is to launch a £14 million pharmacovigilance project focused on using new modelling approaches to facilitate better understanding of adverse drug reactions (ADRs), with AbbVie as project leader.
Translational Quantitative Systems Toxicology to improve the Understanding of the Safety of Medicines (TransQST) is a five-year project funded by the Innovative Medicines Initiative 2 Joint Undertaking (IMI2); its goal is utilise public and private data to develop new tools to create more robust, fit-for-purpose toxicology modelling systems, concerned primarily with providing quantitative risk-assessment in the liver, heart, kidney and gastro-intestinal tract where unpredictable ‘off-target’ reactions are common.
“The fear of ADRs is a major impediment to the development of new, safe and effective therapies,” explained project co-ordinator professor Kevin Park from the University’s Institute of Translational Medicine. “This project will enable us to leverage the best available data and expertise from both public and private domains to generate and validate novel computational models that will help to address the problems of safe drug development. Our ultimate aim is to maximise the benefits of medicines and minimise the harm.”
The project will see eight pharma companies including AbbVie, Eli Lilly, Sanofi, AstraZeneca and GSK join forces with ten academic institutions and three SMEs.
GSK has announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) …
GSK and Save the Children have announced that they will be renewing their partnership for …